New Pricing and Increased Availability | HYPERStack Cell Culture Vessels | Corning

Since 2020, Corning has more than doubled our manufacturing capacity for HYPERStack vessels, upgraded the vessel's design with exterior improvements that enable faster fill and harvest, and introduced new pricing.

All to help you scale out more efficiently than ever.

With Corning HYPERStack cell culture vessels, you can scale your production from the 6,000 cm2of a single 12-layer module to multiple manifolded 36-layer modules delivering more than 500,000 cm2of closed system cell growth area.

New manipulation tools including theHYPERStack Nestand康宁Automated Manipulator Platformcan help to improve process control by consistently placing the vessel in the optimal positions and angles during use.

See how new pricing and increased availability of HYPERStack vessels can help you achieve your goals more cost efficiently.

Learn more about our HYPERStack features and new pricing.

You can either complete ourshort formto have your Corning Account Manager contact you with product, pricing, and demonstration details or view more information on ouronline store.

Do more with Corning HYPERStack Cell Culture Vessels

See how this closed system offers more surface area within a compact footprint.

Watch Now>

康宁HYPERStack in Action

Waisman Biomanufacturing
Waisman Biomanufacturing

Customer Saves Space, Sees COGS Improvement with HYPERStack Vessels

Customer Saves Space, Sees COGS Improvement with HYPERStack Vessels

Read More

Waisman Biomanufacturing — whose cell therapy services include work with MSCs, hESC banks, and a variety of other allogeneic cell therapy lines for human cell therapy applications — recently scaled up capacity at its Madison, Wisc. facility. The company ensured its expansion focused on establishing larger scale manufacturing processes for allogeneic cell therapeutics.

Waisman turned to康宁HYPERStack 36-layer vessels— adherent cell culture platforms that support a faster and more efficient scale-up process. The aim was to increase scale without significantly increasing cost. The change from Waisman’s legacy [cell culture platform] to HYPERStack 36-layer vessels led to “dramatic” COGS improvement. The upgrade represented a roughly 250% increase in cell production capacity for the facility, versus a 20%-25% increase in operating cost. Additionally, the change negated the need to extensively renovate the facility, acquire more incubators, or hire more people.

Waisman Biomanufacturing — whose cell therapy services include work with MSCs, hESC banks, and a variety of other allogeneic cell therapy lines for human cell therapy applications — recently scaled up capacity at its Madison, Wisc. facility. The company ensured its expansion focused on establishing larger scale manufacturing processes for allogeneic cell therapeutics.

Waisman turned to康宁HYPERStack 36-layer vessels— adherent cell culture platforms that support a faster and more efficient scale-up process. The aim was to increase scale without significantly increasing cost. The change from Waisman’s legacy [cell culture platform] to HYPERStack 36-layer vessels led to “dramatic” COGS improvement. The upgrade represented a roughly 250% increase in cell production capacity for the facility, versus a 20%-25% increase in operating cost. Additionally, the change negated the need to extensively renovate the facility, acquire more incubators, or hire more people.

Read More
Cellipont Bioservices
An Inside Look at Overcoming Stem Cell Therapy Scale-up

An Inside Look at Overcoming Stem Cell Therapy Scale-up

An Inside Look at Overcoming Stem Cell Therapy Scale-up

Read More

增加制药indu焦点stry on rapidly growing areas such as cell therapy, drug manufacturers face significant challenges bringing these products to market. Leveraging the experience of those already tackling the complexities of cell therapy manufacturing is on way to accelerate progress.

Dr. Carolyn Wrightson, CTO of Cellipont Bioservices and her team pioneered the historical development of an autologous canine MSC product as well as human MSC drug product manufacture. These milestones ultimately facilitated in early 2020 Cellipont Bioservices’ ability to rapidly develop and manufacture an allogeneic human MSC product (now entering Phase II Clinical Trials) for the treatment of COVID-19 patients suffering from acute respiratory distress syndrome. Dr. Wrightson shares some of the valuable lessons and considerations she and her team learned about stem cell therapy scale up and optimization, including how solutions such as Corning HYPERStack vessels can help support the process.

增加制药indu焦点stry on rapidly growing areas such as cell therapy, drug manufacturers face significant challenges bringing these products to market. Leveraging the experience of those already tackling the complexities of cell therapy manufacturing is on way to accelerate progress.

Dr. Carolyn Wrightson, CTO of Cellipont Bioservices and her team pioneered the historical development of an autologous canine MSC product as well as human MSC drug product manufacture. These milestones ultimately facilitated in early 2020 Cellipont Bioservices’ ability to rapidly develop and manufacture an allogeneic human MSC product (now entering Phase II Clinical Trials) for the treatment of COVID-19 patients suffering from acute respiratory distress syndrome. Dr. Wrightson shares some of the valuable lessons and considerations she and her team learned about stem cell therapy scale up and optimization, including how solutions such as Corning HYPERStack vessels can help support the process.

Read More